Search Results

Business

ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics

ZielBio, Inc. has appointed Alan S. Bash as the company’s new Chief Executive Officer and member of the company’s Board of Directors.

January 3, 2023

·

3 min read

BioCapital

ZielBio to Present Interim Findings from its Phase 1/2, First-in-Human Trial of ZB131 at 2023 ASCO Annual Meeting

ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases, will present the first set of clinical data from its lead asset, ZB131, directed against cancer-specific plectin (CSP), during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 2, 2023

·

2 min read

Policy

ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Pancreatic Cancer

ZielBio, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead program, ZB131, for the treatment of treatment of pancreatic cancer, a rare solid-tumor cancer originating from the pancreas.

December 27, 2022

·

2 min read

BioCapital

ZielBio to Present New Research on the Utility of Cancer-Specific Plectin (CSP) and ZB131 in Antibody-Drug Conjugates at AACR Annual Meeting 2023

ZielBio, Inc. will present new, preclinical data showing that its lead asset, ZB131, directed against cancer-specific plectin (CSP), represents a promising approach for antibody-drug conjugates (ADCs) at the American Association for Cancer Research (AACR) Annual Meeting 2023.

April 17, 2023

·

2 min read

FDA

ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Cholangiocarcinoma

ZielBio, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead program, ZB131, for the treatment of cholangiocarcinoma, a rare solid-tumor cancer originating from the bile duct system.

November 15, 2022

·

2 min read

Drug Development

ZielBio to Present New Data Demonstrating Preclinical Efficacy of ZB131 in Cholangiocarcinoma at AACR Annual Meeting 2022

ZielBio, Inc. will present new, preclinical data on the efficacy of its ZB131 drug in cholangiocarcinoma (CCA) models at the American Association for Cancer Research (AACR) Annual Meeting 2022.

April 12, 2022

·

3 min read

Business

ZielBio Appoints Maria Beconi as Chief Science Officer

ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative ZielFind drug discovery platform, welcomes Maria Beconi, Ph.D., as the company’s chief science officer, and Ramesh Ramanathan, M.D., as vice president for clinical development.

January 20, 2022

·

3 min read

Drug Development

ZielBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of ZB131, Its Novel Monoclonal Antibody Targeting Cancer Specific Plectin

ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer through its innovative ZielFind drug discovery platform, today announced the first patient dosed in its Phase 1/2 clinical trial.

February 15, 2022

·

2 min read

Business

ZielBio Appoints Dieter Weinand Executive Chair as Company Heads Toward the Clinic with Lead Oncology Therapeutic

ZielBio, Inc., an early-stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative drug discovery platform, has appointed industry veteran Dieter Weinand as the company’s new Executive Chair.

December 9, 2020

·

2 min read

Business

ZielBio Closes $25.1 Million Series A Financing

ZielBio, Inc., an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes, has closed a $25.1 million Series A financing round.

September 26, 2019

·

2 min read